Addiction Therapy Services Products

BUPRENORPHINE Sublingual Tablets C-III

PRODUCT DESCRIPTION
Round/White Sublingual Tablets

NDC Number	Strength	Unit Size
0054-0176-13	2 mg	Bottle - 30 tablets
0054-0177-13	8 mg	Bottle - 30 tablets

BUPRENORPHINE AND NALOXONE Sublingual Tablets C-III

PRODUCT DESCRIPTION
Round/Speckled Peach to Peach Sublingual Tablets



NDC Number	Strength	Unit Size
0054-0188-13	2 mg /0 .5 mg	Bottle - 30 tablets
0054-0189-13	8 mg / 2 mg	Bottle - 30 tablets

DISKETS® Dispersible Tablets C-II (Methadone Hydrochloride Tablets for Oral Suspension USP)

PRODUCT DESCRIPTION
Light Pinkish-Orange Cross-Scored Tablets. Orange-Pineapple Flavored

NDC Number	Strength	Unit Size
0054-4538-25	40 mg	Bottle - 100 tablets

METHADONE HCl Tablets USP C-II

PRODUCT DESCRIPTION
Round/White Tablets

BRAND EQUIVALENT
DOLOPHINE®



NDC Number	Strength	Unit Size
0054-4570-25	5 mg	Bottle - 100 tablets
0054-4571-25	10 mg	Bottle - 100 tablets

METHADONE HCl Oral Concentration USP C-II

Product Description	NDC Number	Strength	Unit Size
Clear/Colorless Solution - Flavorless	0054-0391-68	10 mg / mL	1000 mL Bottle
Clear/Red Colored Solution - Cherry flavored	0054-0392-68	10 mg / mL	1000 mL Bottle

Please visit www.hikma.com/us for additional product information, including the Full Prescribing Information with complete indications for use, warnings, precautions and adverse reactions for each product.

NOW AVAILABLE

Buprenorphine and Naloxone Sublingual Film

2 mg/0.5 mg, 4 mg/1 mg, 8 mg/2 mg, and 12 mg/3 mg

A therapeutic equivalent generic version of *Suboxone*® (buprenorphine and naloxone) sublingual film.

BUPRENORPHINE AND NALOXONE SUBLINGUAL FILM

Strength	Packaging	NDC
2 mg/0.5 mg	30 pouches each containing 1 sublingual film	43598-**579**-30
4 mg/1 mg	30 pouches each containing 1 sublingual film	43598-**580**-30
8 mg/2 mg	30 pouches each containing 1 sublingual film	43598-**582**-30
12 mg/3 mg	30 pouches each containing 1 sublingual film	43598-**581**-30

INDICATION

Buprenorphine and naloxone sublingual film is indicated for treatment of opioid dependence. Buprenorphine and naloxone sublingual film should be used as part of a complete treatment plan that includes counseling and psychosocial support.

IMPORTANT SAFETY INFORMATION

Prescription use of this product is limited under the Drug Addiction Treatment Act.

CONTRAINDICATIONS

Buprenorphine and naloxone sublingual film is contraindicated in patients with a history of hypersensitivity to buprenorphine or naloxone as serious adverse reactions, including anaphylactic shock, have been reported.

For additional information, contact your Account Manager or Customer Service at 800-631-2174.

Customer Service
246 Industrial Way West, Eatontown, NJ 07724
Hours: 8am-7pm EST, Monday-Friday
T: 800.631.2174 | F: 732.542.0940
Email: customerservice@hikma.com
www.hikma.com

hikma.